Combination vaccine protects monkeys from ebola and Marburg viruses

Feb 26, 2008

An experimental, combination vaccine against Ebola and Marburg viruses using virus-like particles (VLPs) provides complete protection against infection in monkeys. Researchers from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) report their results today (Feb. 26) at the 2008 ASM Biodefense and Emerging Diseases Research Meeting in Baltimore, MD.

“VLPs are one of the most promising candidates for protecting humans against Ebola and Marburg virus infections,” says Dr. Kelly Warfield, a researcher at USAMRIID who presented the study. They could also be safer than other vaccine candidates.

Traditionally vaccines against viral diseases have consisted of whole viruses, either the one that causes the disease in a weakened or dead state (like the polio vaccine) or a genetically similar virus that does not usually cause disease but elicits a protective immune response. The problem with this approach is there is the risk, however small, of viral reactivation and infection.

“Since the VLP vaccine does not use a whole virus, there is no chance of infection,” says Warfield, who notes that some VLP-based vaccines, such as the human papillomavirus (HPV) vaccine, are already on the market.

To create the vaccine, Warfield and her colleagues infected insect cells with specially engineered baculoviruses. The infected cells then produced VLPs for either Marburg or Ebola, depending on the baculovirus, which were then purified. They mixed the two together and vaccinated the monkeys with it.

“Following challenge with Ebola or Marburg virus, all the VLP-vaccinated monkeys survived challenge without clinical or laboratory signs of infection, while the control animals succumbed to the infection,” says Warfield. “Based on their safety profile, immunogenicity and protective efficacy, the VLPs are a leading candidate for use as a filovirus vaccine in humans.”

Additionally, Warfield discovered that vaccination with one strain of Marburg VLP produced protection against 3 different strains of the virus, which is surprising. Subunit vaccines (in which only part of the virus is used) had previously not been thought to confer broad-based immunity.

Researchers are currently working on scaling up the production process and hope to begin clinical trials in humans in a few years.

Source: American Society for Microbiology

Explore further: EU regulator: Morning-after pill OK for all women

add to favorites email to friend print save as pdf

Related Stories

West African bats—no safe haven for malaria parasites

Oct 21, 2013

In Europe, bats are normally discussed in the context of endangered species threatened by loss of their habitats. However, in recent years, bats have caught the eye of infection biologists. The animals are ...

Scientists reveal how deadly Ebola virus assembles

Aug 15, 2013

Scientists at The Scripps Research Institute (TSRI) have discovered the molecular mechanism by which the deadly Ebola virus assembles, providing potential new drug targets. Surprisingly, the study showed ...

Small molecules may prevent ebola infection

Jan 19, 2011

Ebola, a virus that causes deadly hemorrhagic fever in humans, has no known cure or vaccine. But a new study by University of Illinois at Chicago scientists has uncovered a family of small molecules which appear to bind to ...

Origins of the pandemic: Study reveals lessons of H1N1

Jan 13, 2011

As H1N1 'Swine Flu' returns to the national headlines a new research paper reveals the key lessons about the origins of the 2009 pandemic. The paper, published today in BioEssays, reveals how the pandemic challenges the tr ...

Recommended for you

EU regulator: Morning-after pill OK for all women

15 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

19 hours ago

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

Zydelig approved for three types of blood cancer

20 hours ago

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...

Journal raises concern about blood-thinning drug

Jul 23, 2014

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

User comments : 0